ArticleAnnals of medicine2025
Anoikis-related genes predicts prognosis and therapeutic response in renal cell carcinoma.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastasis represents the primary cause of cancer-related mortality, with a high incidence observed in renal cell carcinoma (RCC). Anoikis, a specialized form of apoptosis, plays a crucial role in preventing displaced cells from adhering to new extracellular matrices (ECM), thus inhibiting their aberrant growth. Notably, cancer cells, especially metastatic ones, exhibit resistance to anoikis. However, the exact mechanisms of anoikis resistance in RCC are not well understood.
methodsThis study integrates bioinformatics, single-cell RNA sequencing and experimental validation to investigate the role of anoikis-related genes (ARG) in RCC, with a focus on MMP9. RNA-seq data from 518 RCC patients and 71 healthy controls (TCGA-KIRC) and external validation cohorts (E-MTAB-1980, GSE22541) were analyzed to construct an ARG-based prognostic model. Single-cell RNA sequencing (scRNA-seq, GSE159115) was used to assess tumour heterogeneity, while
resultsWe collected all RNA-seq and single-cell RNA-seq (scRNA-seq) data from multiple online databases and utilized these datasets to develop a novel ARG-based prognostic model called ARGs. Using Cox regression and machine learning, our model achieved a 5-year area under curve (AUC) of 0.79, surpassing existing models in predictive performance. Enrichment analysis revealed distinct immune and metabolic landscapes between ARGs high- and low-risk groups. At the single-cell level, tumour cells were categorized based on ARG expression, revealing heterogeneous anoikis resistance mechanisms. MMP9 was identified as a key prognostic gene (HR = 1.5,
conclusionsTargeting anoikis-related genes, particularly MMP9, enhances anoikis sensitivity and reduces RCC invasiveness, offering a potential therapeutic strategy to mitigate metastasis and improve clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.